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Abstract
Background: Although some epidemiologic studies found inverse associations between alcohol drinking and
Parkinson’s disease (PD), the majority of studies found no such significant associations. Additionally, there is only
limited research into the possible interactions of alcohol intake with aldehyde dehydrogenase (ALDH) 2 activity
with respect to PD risk. We examined the relationship between alcohol intake and PD among Japanese subjects
using data from a case-control study.
Methods: From 214 cases within 6 years of PD onset and 327 controls without neurodegenerative disease, we
collected information on “peak”, as opposed to average, alcohol drinking frequency and peak drinking amounts
during a subject’s lifetime. Alcohol flushing status was evaluated via questions, as a means of detecting inactive
ALHD2. The multivariate model included adjustments for sex, age, region of residence, smoking, years of education,
body mass index, alcohol flushing status, presence of selected medication histories, and several dietary factors.
Results: Alcohol intake during peak drinking periods, regardless of frequency or amount, was not associated with
PD. However, when we assessed daily ethanol intake separately for each type of alcohol, only Japanese sake (rice
wine) was significantly associated with PD (adjusted odds ratio of ≥66.0 g ethanol per day: 3.39, 95% confidence
interval: 1.10-11.0, P for trend = 0.001). There was no significant interaction of alcohol intake with flushing status in
relation to PD risk.
Conclusions: We did not find significant associations between alcohol intake and PD, except for the daily amount
of Japanese sake. Effect modifications by alcohol flushing status were not observed.
Background
While smoking has been consistently associated with a
decreased risk of Parkinson’s disease (PD), a relationship
between alcohol intake and PD still remains controver-
sial. Some epidemiological studies reported that alcohol
drinking was inversely associated with PD [1-4]. Conver-
sely, the vast majority of investigations failed to find sig-
nificant associations between alcohol intake and PD
[5-13]. In a meta-analysis comparing drinkers with non-
drinkers, the pooled odds ratio (OR) for PD risk was
0.81 (95% confidence interval (CI): 0.70-0.92) or 0.73
(95% CI: 0.57-0.92) when 13 case-control studies or 4
cohort studies, respectively, were included [14].
Alcohol drinking status, including frequency and
amount, can be influenced by activities of alcohol dehy-
drogenases (ADHs) and aldehyde dehydrogenases
(ALDHs). ALDH2, a key enzyme in the elimination of
acetaldehyde, has a polymorphism that is prevalent in
East Asians, but rare in Caucasians or Africans [15].
Those with inactive ALDH2 are likely to experience
facial flushing responses due to acetaldehydemia after
drinking alcohol, resulting in reduced alcohol intake
with respect to both frequency and amount [16-19]. It
has been reported that those with flushing responses
drank significantly less hard liquor than those without
[19]. Because aldehydes may react with dopamine both
in vitro and in vivo [20,21], it might be hypothesized
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ing to flushing status. To our knowledge, only one
study, a case-control study from Japan, investigated a
possible effect modification by ALDH2 activity and
found that average alcohol consumption was signifi-
cantly lower among cases than controls regardless of
ALDH2 genotype [3].
In the present study, we examined the association
between alcohol drinking and PD risk using data from a
hospital-based case-control study among Japanese. We
also investigated whether flushing status, as a proxy
variable of ALDH2 activity, modified the association.
Methods
Study subjects
Methodologies used in this study have been described
previously [22,23]. Cases were recruited at 11 collaborat-
ing hospitals in Japan: 1 national and 3 university hospi-
tals in Fukuoka, the largest prefecture in Kyushu Island
in southern Japan, and 1 municipal, 3 university, and 3
national hospitals in Osaka, Kyoto, and Wakayama Pre-
fectures, which are part of the Kinki region located in
the midwestern part of Japan. Eligible cases were
patients within 6 years of the onset of PD who had
received treatment at one of the collaborating hospitals
during the period from April 1, 2006 to March 31, 2008.
The collaborating neurologists were responsible for the
PD diagnoses, which were based on the UK PD Society
Brain Bank clinical diagnostic criteria [24]. The neurolo-
gists in charge asked 298 eligible PD patients to take
part: 250 were cooperative in answering the question-
naires and 48 declined (response rate: 84%).
Recruitment of control subjects was conducted at 3 of
the same 11 hospitals: 1 university hospital in Fukuoka
Prefecture, and 1 university and 1 national hospital in
the Kinki region. Eligible control subjects were inpati-
ents and outpatients without neurodegenerative diseases
recruited from departments other than neurology (i.e.,
orthopedic surgery, ophthalmology, otorhinolaryngology,
plastic surgery, and oral surgery) during the period from
A p r i l1 ,2 0 0 6t oM a r c h3 1 ,2 0 0 8 .C o n t r o l sw e r en o t
matched to cases either individually or by group. A total
of 528 patients were approached by their attending phy-
sicians or our research nurses for recruitment as con-
trols; 372 agreed and 156 declined (response rate: 70%).
The study protocol was approved by the ethics commit-
tees of the 11 collaborating hospitals and written con-
sent was obtained from all subjects.
Information collection
Cases and controls filled out a set of 2 self-administered
questionnaires and mailed them to the data manage-
ment center or handed them to research nurses.
Research technicians completed missing or corrected
illogical data by telephone or direct interview. One ques-
tionnaire was used to collect information on “peak”,a s
opposed to average, alcohol drinking status during a
subject’s lifetime. Subjects were asked to provide infor-
mation on their drinking habits during the period in
which alcohol consumption was the highest. We
assessed drinking frequency, as well as volume of alco-
hol intake according to beverage types. The volume was
subsequently converted to grams of ethanol, and values
for each beverage type were added. The ethanol con-
tents for calculation were as follows: 4.5% for beer,
15.5% for Japanese sake (rice wine), 25% for shochu
(a distilled alcoholic beverage made in Japan), 12% for
wine, and 43% for whisky. Both the daily and the weekly
amounts of alcohol intake during the peak drinking
period (for cases, only time prior to onset of PD) were
estimated for each subject. The questionnaire also eli-
cited information on several factors such as sex, age,
smoking, education, and presence of medication history
for hypertension, hypercholesterolemia, and diabetes.
Although its validity has not been investigated, the ques-
tionnaire for this study was developed based on a com-
prehensive literature review of epidemiologic studies of
factors associated with PD.
Alcohol flushing status was evaluated via questions as
a proxy for detecting inactive ALHD2 [25], as follows:
(a) Do you have tendency to flush in the face immedi-
ately after drinking a glass of beer (yes, no, or
unknown)? (b) Did you have a tendency to flush in the
face immediately after drinking a glass of beer during
the first to second year after you started drinking (yes,
no, or unknown)? Subjects who answered, “yes” to ques-
tion (a) were classified as “current flushing”,w h e r e a s
those who answered “yes” to question (b) but not to
question (a) were classified as “former flushing”.T h e
remaining subjects were classified as “never flushing”.
Among cancer-free Japanese men, when current or for-
mer flushing individuals were considered to have inac-
tive ALDH2, the sensitivity and specificity of the
questions were 90.1% and 88.0%, respectively [25].
Dietary habits during the preceding month were
assessed using a self-administered, semi-quantitative,
comprehensive diet history questionnaire (DHQ). Details
of the DHQ’s structure, calculation of dietary intake,
and validity for commonly studied nutritional factors
have been published elsewhere [26]. Dietary glycemic
index, a measure of carbohydrate quality, not quantity,
was calculated as described elsewhere [27]. In a valida-
tion study of 92 Japanese women and 92 Japanese men,
Pearson’s correlation coefficients between the DHQ and
16-day weighed dietary records were 0.43 and 0.38 for
caffeine, 0.42 and 0.49 for cholesterol, 0.42 and 0.48 for
vitamin E, 0.63 and 0.58 for vitamin B6, 0.68 and 0.52
for iron, and 0.50 and 0.58 for the dietary glycemic
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tions, 2006]. Except for dietary glycemic index, dietary
variables were energy-adjusted using the density method
(amount per 4184 kJ of energy). Body weight and height
were self-reported as part of the DHQ. Body mass index
was calculated as weight (kg) divided by the square of
height (m).
Because we failed to obtain information on peak alco-
hol drinking from 69 former drinkers (32 cases and 37
controls), they were eliminated from the analysis. Also
excluded were 2 cases without available information on
peak drinking prior to the onset of PD and 1 case and 4
controls whose information on any of the alcohol-
related factors was missing. After further exclusion of 1
case and 4 controls due to missing data on other factors
under study, 214 cases and 327 controls were subjected
to final analysis.
Statistical analysis
Frequency and amount of alcohol drinking were cate-
gorized into 3 levels based on the distribution of con-
trols: 1) never drinkers, 2) current drinkers who
consumed alcohol <6 days per week for frequency,
0.1-65.9 grams ethanol per day for daily amounts, and
0.1-219.3 grams per week for weekly amounts, and 3)
current drinkers who consumed alcohol ≥6 days per
week for frequency, ≥66.0 grams ethanol per day for
daily amounts, and ≥219.4 grams per week for weekly
amounts. Logistic regression analyses were employed to
estimate ORs and 95% CIs of alcohol, using non-drinker
as the reference category. The trend of association was
assessed by assigning ordinal scores to the levels of
independent variables.
The primary multivariate model included adjust-
ments for sex, age, region of residence, pack-years of
smoking, years of education, body mass index, alcohol
flushing status, and presence of medication history (for
hypertension, hypercholesterolemia, and diabetes) as
potential confounders. Region of residence was classi-
fied into 2 categories (Fukuoka and Kinki); pack-years
(1 pack/day for 1 yr) of smoking into 3 (none, 0.1-
29.9, and ≥30.0); years of education into 3 (<10, 10-12,
and ≥13 years); flushing status into 2 (never and for-
mer/current flushing); and presence of medication his-
tory into 2 (yes or no for each disease category). Age
and body mass index were included as continuous
variables. The fully adjusted model additionally incor-
porated several dietary factors including caffeine, cho-
lesterol, vitamin E, vitamin B6, iron, and the dietary
glycemic index as continuous variables. We also tested
for statistical interactions of alcohol intake with flush-
ing status by including product terms as independent
variables in a fully adjusted model. All hypothesis test-
ing was conducted assuming a 0.05 significance level
and a 2-sided alternative hypothesis. SAS version 9.1
(SAS Institute, Inc., Cary, NC) was used throughout
the analysis.
Results
Thirty-five percent of the subjects were male and the
mean age was approximately 70 years (Table 1). Com-
pared with control subjects, cases were more likely to be
older and thinner, report never having smoked, report
Table 1 Characteristics of the study population
Variable n (%) or mean (SD) P-
value
Cases
(N = 214)
Controls
(N = 327)
Sex (%) 0.86
Male 73 (34.1) 114 (34.9)
Female 141 (65.9) 213 (65.1)
Age (y) 67.9 (8.5) 66.4 (8.6) 0.04
Region of residence (%) 0.43
Fukuoka 81 (37.9) 135 (41.3)
Kinki 133 (62.2) 192 (58.7)
Pack-years of smoking (%) 0.007
None 164 (76.6) 211 (64.5)
0.1-29.9 28 (13.1) 55 (16.8)
≥ 30.0 22 (10.3) 61 (18.7)
Education (%) 0.74
< 10 y 39 (18.2) 64 (19.6)
10-12 y 110 (51.4) 157 (48.0)
≥ 13 y 65 (30.4) 106 (32.4)
Body mass index (kg/m
2) 22.4 (3.3) 23.0 (3.3) 0.04
Current drinking (%) 0.71
No 115 (53.7) 181 (55.4)
Yes 99 (46.3) 146 (44.7)
Alcohol flushing status (%) 0.39
Never flushing 107 (50.0) 166 (50.8)
Former flushing 4 (1.9) 2 (0.6)
Current flushing 103 (48.1) 159 (48.6)
Presence of medication history
(%)
Hypertension 50 (23.4) 123 (37.6) 0.0005
Hypercholesterolemia 20 (9.4) 52 (15.9) 0.028
Diabetes mellitus 9 (4.2) 29 (8.9) 0.038
Daily intake
a
Total energy (kJ) 8418.6
(2546.8)
8388.6
(3145.4)
0.90
Caffeine (mg/4184 KJ) 153.0 (112.2) 194.6 (139.2) 0.0001
Cholesterol (mg/4184 KJ) 157.8 (60.0) 147.7 (60.9) 0.06
Vitamin E (mg/4184 KJ) 4.2 (1.2) 4.2 (1.2) 0.88
Vitamin B-6 (mg/4184 KJ) 0.6 (0.2) 0.6 (0.2) 0.94
Iron (mg/4184 KJ) 3.8 (0.9) 3.8 (1.0) 0.47
Dietary glycemic index 64.9 (4.7) 65.4 (5.2) 0.27
a Nutrient intake was adjusted for total energy intake using the density
method, except for dietary glycemic index.
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hypercholesterolemia, or diabetes, and have a low intake
of caffeine. There were no differences with respect to
both the status of current drinking and alcohol flushing
status, as well as sex, region of residence, education, and
the other dietary variables.
In crude analyses, neither frequency nor amount of
alcohol intake during the peak drinking period was sig-
nificantly associated with the risk of PD among all sub-
jects (Table 2). After adjustment for several potential
confounders including sex, age, region of residence,
pack-years of smoking, years of education, body mass
index, flushing status, and presence of selected medica-
tion history, the association between weekly alcohol
intake and PD was strengthened. Compared with non-
drinkers, the OR of those who drank ≥219.4 g ethanol
per week was 2.09 (95% CI: 1.13-3.91, P for trend =
0.03). The confounding was primarily due to smoking,
not flushing status (data not shown). This positive rela-
tionship disappeared, however, when caffeine, choles-
terol, vitamin E, vitamin B6, iron, and the dietary
glycemic index were further included as confounders
(OR: 1.79, 95% CI: 0.95-3.39, P for trend = 0.11). Like-
wise, no significant associations were observed between
f r e q u e n c yo rd a i l ye t h a n o li n t a k ea n dt h er i s ko fP Di n
the fully adjusted model: the adjusted OR of the highest
category (≥6 days per week and ≥66.0 g ethanol per day)
was 0.96 for the frequency (95% CI: 0.50-1.81, P for
trend = 0.96) and 1.46 for the daily amount (95% CI:
0.79-2.71, P for trend = 0.26).
When we assessed daily ethanol intake separately for
each type of alcohol, there were no significant associa-
tions with PD, except for Japanese sake (Table 3). The
OR of the highest category (≥66.0 g ethanol per day) in
the fully adjusted model was 2.13 for beer (95% CI:
0.80-5.82, P for trend = 0.39), 3.39 for Japanese sake
(95% CI: 1.10-11.0, P for trend = 0.001), 1.29 for shochu
(95% CI: 0.59-2.78, P for trend = 0.58), 6.11 for wine
(95% CI: 0.67-134, P for trend = 0.36) and 2.25 for
whisky (95% CI: 0.67-7.83, P for trend = 0.06). We
could not examine the frequency or weekly amount of
alcohol intake for the individual types of alcohol because
we did not ask information on drinking frequency sepa-
rately for each type of alcohol.
In the stratified analysis according to flushing status,
former and current flushers were combined due to
small numbers of former flushers (Table 4). We did not
find any significant interactions between alcohol drink-
ing and flushing status with regard to the risk of PD (P
for interaction = 0.22, 0.37, and 0.18 for the highest
category of frequency, daily amount, and weekly amount
of alcohol intake, respectively). With respect to the sepa-
rate types of alcohol, no interactions with flashing status
were observed.
Table 2 ORs for Parkinson’s disease in relation to alcohol drinking during “peak” period
Alcohol drinking during “peak” period
a n (%) Crude OR
(95% CI)
Adjusted OR
b
(95% CI)
Adjusted OR
c
(95% CI)
Cases (N = 214) Controls (N = 327)
Frequency
Non-drinker 115 (53.7) 181 (55.4) 1.00 1.00 1.00
< 6 days per week 63 (29.4) 77 (23.6) 1.29 (0.86-1.93) 1.46 (0.90-2.36) 1.29 (0.78-2.13)
≥ 6 days per week 36 (16.8) 69 (21.1) 0.82 (0.51-1.30) 1.13 (0.61-2.10) 0.96 (0.50-1.81)
P for trend 0.70 0.50 0.96
Amount per day (ethanol, g)
Non-drinker 115 (53.7) 181 (55.4) 1.00 1.00 1.00
0.1-65.9 46 (21.5) 73 (22.3) 0.99 (0.64-1.53) 1.20 (0.72-1.97) 1.07 (0.64-1.80)
≥ 66.0 53 (24.8) 73 (22.3) 1.14 (0.75-1.74) 1.75 (0.97-3.20) 1.46 (0.79-2.71)
P for trend 0.58 0.07 0.26
Amount per week (ethanol, g)
Non-drinker 115 (53.7) 181 (55.4) 1.00 1.00 1.00
0.1-219.3 41 (19.2) 73 (22.3) 0.88 (0.56-1.38) 1.11 (0.67-1.83) 0.98 (0.58-1.65)
≥ 219.4 58 (27.1) 73 (22.3) 1.25 (0.82-1.90) 2.09 (1.13-3.91) 1.79 (0.95-3.39)
P for trend 0.38 0.03 0.11
OR, odds ratio; CI, confidence interval.
a Defined as period during which the subject’s alcohol consumption was the highest.
b Adjusted for sex, age, region of residence, pack-years of smoking, years of education, body mass index, alcohol flushing status, and presence of medication
history for hypertension, hypercholesterolemia, and diabetes.
c Adjusted for sex, age, region of residence, pack-years of smoking, years of education, body mass index, alcohol flushing status, presence of medication history
for hypertension, hypercholesterolemia, and diabetes, dietary intake of caffeine, cholesterol, vitamin E, vitamin B6, iron, and dietary glycemic index.
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In this study, alcohol intake during the peak drinking
period was not associated with PD when ethanol intake
was combined from all types of alcohol. There was no
significant interaction of alcohol drinking with flushing
status in relation to PD risk. Similarly to the present
study, a substantial body of previous case-control studies
failed to find significant associations between alcohol
and PD. In each study, alcohol as an exposure variable
was assessed differently, including as a binary category
of “ever vs. never” [5-8,12,13], an average amount [12], a
cumulative amount [10], or amount per week based on
typical consumption patterns during most of the sub-
ject’s adult life [9]. A large prospective cohort study,
including two cohorts from the Nurses’ Health Study
and Health Professionals’ Study, found no significant
relationship between average alcohol intake at baseline
and subsequent PD incidence [11].
Our finding is not in agreement with previous studies
that observed significant inverse associations between
alcohol intake and PD [1-4]. A meta-analysis reported a
reduced risk of PD among drinkers compared with non-
drinkers: the pooled OR (95% CI) was 0.81(0.70-0.92) or
0.73 (0.57-0.92) when 13 case-control studies or 4
cohort studies, respectively, were included [14]. Several
epidemiologic studies found that beer [11,28,29], spirits
[28], wine [29] and liquor [2,29], but not ethanol intake
[11,28], were inversely associated with PD. The high
content of urate in beer or niacin in alcoholic beverages
were reported as plausible protective agents [30,31].
Another hypothesis is that PD patients have a premor-
bid personality to avoid alcohol drinking. Two previous
Table 3 ORs for Parkinson’s disease in relation to alcohol drinking amount per day during “peak” period according to
types of alcohol
Alcohol drinking amount per day during
“peak” period (ethanol, g)
a
n (%) Crude OR
(95% CI)
Adjusted OR
b
(95% CI)
Adjusted OR
c
(95% CI)
Cases
(N = 214)
Controls
(N = 327)
Beer
Non-drinker 127 (59.4) 195 (59.6) 1.00 1.00 1.00
0.1-65.9 75 (35.1) 121 (37.0) 0.95 (0.66-1.37) 1.14 (0.72-1.79) 0.99 (0.61-1.59)
≥ 66.0 12 (5.6) 11 (3.4) 1.68 (0.71-3.97) 2.23 (0.84-5.97) 2.13 (0.80-5.82)
P for trend 0.62 0.19 0.39
Japanese sake (rice wine)
Non-drinker 146 (68.2) 261 (79.8) 1.00 1.00 1.00
0.1-65.9 58 (27.1) 59 (18.0) 1.76 (1.16-2.66) 2.42 (1.44-4.11) 2.27 (1.34-3.89)
≥ 66.0 10 (4.7) 7 (2.1) 2.55 (0.96-7.17) 3.10 (1.04-9.71) 3.39 (1.10-11.0)
P for trend 0.002 0.001 0.001
Shochu (a distilled alcoholic beverage made in Japan)
Non-drinker 180 (84.1) 273 (83.5) 1.00 1.00 1.00
0.1-65.9 18 (8.4) 32 (9.8) 0.85 (0.46-1.55) 1.07 (0.54-2.08) 1.01 (0.50-1.98)
≥ 66.0 16 (7.5) 22 (6.7) 1.10 (0.56-2.15) 1.50 (0.69-3.21) 1.29 (0.59-2.78)
P for trend 0.98 0.34 0.58
Wine
Non-drinker 187 (87.4) 294 (89.9) 1.00 1.00 1.00
0.1-65.9 24 (11.2) 32 (9.8) 1.18 (0.67-2.06) 1.21 (0.66-2.21) 1.06 (0.57-1.95)
≥ 66.0 3 (1.4) 1 (0.3) 4.72 (0.60-95.7) 6.88 (0.75-153) 6.11 (0.67-134)
P for trend 0.24 0.18 0.36
Whisky
Non-drinker 177 (82.7) 283 (86.5) 1.00 1.00 1.00
0.1-65.9 30 (14.0) 38 (11.6) 1.26 (0.75-2.11) 1.62 (0.89-2.94) 1.60 (0.88-2.93)
≥ 66.0 7 (3.3) 6 (1.8) 1.87 (0.61-5.88) 2.72 (0.82-9.34) 2.25 (0.67-7.83)
P for trend 0.17 0.03 0.06
OR, odds ratio; CI, confidence interval.
a Defined as period during which the subject’s alcohol consumption was the highest.
b Adjusted for sex, age, region of residence, pack-years of smoking, years of education, body mass index, alcohol flushing status, and presence of medication
history for hypertension, hypercholesterolemia and diabetes.
c Adjusted for sex, age, region of residence, pack-years of smoking, years of education, body mass index, alcohol flushing status, presence of medication history
for hypertension, hypercholesterolemia and diabetes, dietary intake of caffeine, cholesterol, vitamin E, vitamin B6, iron, and dietary glycemic index.
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nificantly less likely to have been diagnosed with alco-
holism or to have a previous history of alcohol use
disorder [8,13].
When we examined daily ethanol intake separately for
e a c ht y p eo fa l c o h o l ,o n l yJ a p a n e s es a k ew a sp o s i t i v e l y
associated with PD. To our knowledge, there has been no
report that Japanese sake increased the risk of PD.
Although our finding could be due to chance, it has been
shown that relationships between alcohol intake and PD
varied according to different kinds of alcohol [11,28,29].
In vitro studies showed that aldehydes might react
with dopamine. Ethanol enhanced the toxicity of 6-
hydroxydopamin (6-OHDA) when ethanol and 6-OHDA
were simultaneously applied to cultured cells [20]. In an
attempt to create a mouse version of the rat model of
PD, developed using a synthetic proteasome inhibitor
(PSI), decreased levels of nigrostriatal dopamine were
observed both in the mice treated with PSI in an etha-
nol-vehicle and in control mice with ethanol-vehicle
alone [21]. By contrast, it was reported that ADHs, and
not ALDHs, play important roles in the synthesis of
Table 4 ORs for Parkinson’s disease in relation to alcohol drinking during “peak” period by flushing status
Alcohol drinking during “peak” period
a n (%) Crude OR
(95% CI)
Adjusted OR
b
(95% CI)
Adjusted OR
c
(95% CI)
Never flushing Cases
(N = 107)
Controls
(N = 166)
Frequency
Non-drinker 79 (73.8) 127 (76.5) 1.00 1.00 1.00
< 6 days per week 23 (21.5) 24 (14.5) 1.54 (0.81-2.92) 1.65 (0.80-3.44) 1.32 (0.60-2.93)
≥ 6 days per week 5 (4.7) 15 (9.0) 0.54 (0.17-1.44) 0.78 (0.22-2.54) 0.61 (0.17-1.99)
P for trend 0.82 0.67 0.77
Amount per day (ethanol, g)
Non-drinker 79 (73.8) 127 (76.5) 1.00 1.00 1.00
0.1-65.9 17 (15.9) 21 (12.7) 1.30 (0.64-2.61) 1.33 (0.61-2.87) 1.07 (0.47-2.43)
≥ 66.0 11 (10.3) 18 (10.8) 0.98 (0.43-2.16) 1.54 (0.54-4.39) 1.11 (0.37-3.31)
P for trend 0.80 0.32 0.82
Amount per week (ethanol, g)
Non-drinker 79 (73.8) 127 (76.5) 1.00 1.00 1.00
0.1-219.3 19 (17.8) 23 (13.9) 1.33 (0.68-2.59) 1.46 (0.69-3.09) 1.18 (0.53-2.63)
≥ 219.4 9 (8.4) 16 (9.6) 0.90 (0.37-2.11) 1.24 (0.42-3.60) 0.89 (0.29-2.66)
P for trend 0.85 0.44 0.99
Former/current flushing Cases
(N = 107)
Controls
(N = 161)
Frequency
Non-drinker 36 (33.6) 54 (33.5) 1.00 1.00 1.00
< 6 days per week 40 (37.4) 53 (32.9) 1.13 (0.63-2.04) 1.12 (0.56-2.26) 0.97 (0.47-2.02)
≥ 6 days per week 31 (29.0) 54 (33.5) 0.86 (0.47-1.59) 0.98 (0.43-2.26) 0.84 (0.35-2.00)
P for trend 0.64 0.96 0.68
Amount per day (ethanol, g)
Non-drinker 36 (33.6) 54 (33.5) 1.00 1.00 1.00
0.1-65.9 29 (27.1) 52 (32.3) 0.84 (0.45-1.55) 0.97 (0.48-1.97) 0.84 (0.40-1.77)
≥ 66.0 42 (39.3) 55 (34.2) 1.15 (0.64-2.06) 1.38 (0.61-3.17) 1.16 (0.49-2.74)
P for trend 0.63 0.44 0.71
Amount per week (ethanol, g)
Non-drinker 36 (33.6) 54 (33.5) 1.00 1.00 1.00
0.1-219.3 22 (20.6) 50 (31.1) 0.66 (0.34-1.26) 0.79 (0.38-1.64) 0.66 (0.30-1.43)
≥ 219.4 49 (45.8) 57 (35.4) 1.29 (0.73-2.29) 2.06 (0.88-4.96) 1.82 (0.75-4.53)
P for trend 0.33 0.13 0.23
OR, odds ratio; CI, confidence interval.
a Defined as period during which the subject’s alcohol consumption was the highest.
b Adjusted for sex, age, region of residence, pack-years of smoking, years of education, body mass index, and presence of medication history for hypertension,
hypercholesterolemia, and diabetes.
c Adjusted for sex, age, region of residence, pack-years of smoking, years of education, body mass index, presence of medication history for hypertension,
hypercholesterolemia, and diabetes, dietary intake of caffeine, cholesterol, vitamin E, vitamin B6, iron, and dietary glycemic index.
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ment and maintenance of the dopaminergic system [32].
These inconsistent findings may explain the lack of sig-
nificant interaction we observed between alcohol drink-
ing and flushing status in relation to PD risk.
A strength of the present study is that cases were
identified using strict diagnostic criteria, minimizing dis-
ease misclassification as much as possible. We also
designed our study with extensive data collection, based
on comprehensive literature review, allowing us to
adjust for several potential confounders, including diet-
ary factors. However, residual confounding cannot be
ruled out. In contrast to previous studies that looked at
average drinking habits, we examined subjects’ peak
drinking status as exposure variables. Some PD patients
experience several gastrointestinal symptoms as non-
motor manifestations. It was shown that constipation,
occurring as early as 20 or more years before the onset
of motor symptoms, was associated with an increased
risk of PD [33]. Given that some gastrointestinal symp-
toms such as constipation affect alcohol drinking status
even before the onset of disease, average or cumulative
drinking amounts might be decreased in PD patients
compared with healthy subjects. Thus the peak drinking
status may be another reasonable indicator to avoid
underestimation of alcohol consumption among PD
patients.
Our study was limited by our failure to collect infor-
mation on peak drinking from former drinkers (approxi-
mately 10% of the subjects initially recruited for the
present study). A comparison of the 541 subjects
included in the final analysis with 69 former drinkers
revealed that former drinkers were more likely to be
male (63.8 vs. 34.6%, P <0.0001), older (mean age: 70.2
vs. 67.0, P = 0.003), smokers (those with ≥30.0 pack-
years: 36.2 vs. 15.3%, P <0.0001), more educated (those
with ≥13 years: 34.8 vs. 31.6%, P = 0.006), and have a
medication history for diabetes (15.9 vs. 7.0%, P =0 . 0 1 ) .
We previously revealed an inverse association between
smoking habits or medication history for diabetes and
PD in this study population [22,23]. By contrast, ageing
is known to be strong positive risk factor for PD; there-
fore, selection bias might not be negligible, although we
cannot precisely speculate on either the direction or the
magnitude of the bias.
Another possible limitation is that our controls were
not fully representative of the population from which
our cases arose, as they were selected from only 3 of the
11 collaborating hospitals where cases were recruited.
The results of a sensitivity analysis restricted to cases
who were recruited from the three hospitals associated
with control recruitment (n = 130) were similar to those
in the overall analysis: the adjusted OR in the highest
category was 0.78 (95% CI: 0.36-1.63, P for trend = 0.59)
for frequency, 1.17 (95% CI: 0.58-2.36, P for trend =
0.71) for daily amount, and 1.66 (95% CI: 0.81-3.42,
P for trend = 0.26) for weekly amount. Furthermore,
cases in the present study were prevalent rather than
incident cases. When we conducted a sensitivity analysis
confined to cases less than 3 years from onset (n = 88),
interpretation of our results was not markedly changed.
The adjusted OR in the highest category was 0.60 (95%
CI: 0.24-1.42, P for trend = 0.32) for frequency, 1.28
(95% CI: 0.58-2.82, P for trend = 0.69) for daily amount,
and 1.50 (95% CI: 0.67-3.36, P for trend = 0.51) for
weekly amount. We were also concerned that medica-
tion history might affect alcohol drinking habits, so we
performed a sensitivity analysis among subjects without
medication history for hypertension, hypercholesterole-
mia, or diabetes (152 cases and 173 controls). The asso-
ciations between alcohol intake and PD were not
considerably altered. The adjusted OR in the highest
category was 0.91 (95% CI: 0.41-2.00, P for trend = 0.94)
for frequency, 1.34 (95% CI: 0.62-2.93, P for trend =
0.47) for daily amount, and 1.61 (95% CI: 0.75-3.50, P
for trend = 0.27) for weekly amount. Thus, the possible
influence of medication history on alcohol intake was, if
any, likely to be minimal. Finally, all the information in
this study relied on self-reports rather than on inter-
views by trained investigators, and information on alco-
hol intake and non-dietary factors was collected via a
non-validated questionnaire, which could affect the pre-
sent results.
Conclusions
We did not find significant associations between alcohol
intake and PD, except for the daily amount of Japanese
sake. Effect modifications by alcohol flushing status
were not observed. The present study, however, is the
first to assess the effects of alcohol on PD risk using
peak drinking status as an exposure variable and alcohol
flushing status as a potential confounder. To better
understand the role of alcohol drinking in the pathogen-
esis of PD, it may be helpful to take into consideration
many aspects of alcohol.
Appendix
Other members of the Fukuoka Kinki Parkinson’sD i s -
ease Study Group are as follow: Yasuhiko Baba and
Tomonori Kobayashi (Department of Neurology,
Faculty of Medicine, Fukuoka University); Hideyuki
Sawada, Eiji Mizuta, and Nagako Murase (Clinical
Research Institute and Department of Neurology,
Utano National Hospital); Tsuyoshi Tsutada and Hir-
oyuki Shimada (Department of Geriatrics and Neurol-
ogy, Osaka City University Graduate School of
Medicine); Jun-ichi Kira (Department of Neurology,
Neurological Institute, Graduate School of Medical
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Page 7 of 9Sciences, Kyushu University); Tameko Kihira and
Tomoyoshi Kondo (Department of Neurology,
Wakayama Medical University); Hidekazu Tomimoto
(Department of Neurology, Kyoto University Graduate
School of Medicine); Takayuki Taniwaki (Division of
Respirology, Neurology, and Rheumatology, Depart-
ment of Medicine, Kurume University School of Medi-
cine); Hiroshi Sugiyama and Sonoyo Yoshida
(Department of Neurology, Minami-Kyoto National
Hospital); Harutoshi Fujimura and Tomoko Saito
(Department of Neurology, Toneyama National Hospi-
tal); Kyoko Saida and Junko Fujitake (Department of
Neurology, Kyoto City Hospital); Naoki Fujii (Depart-
ment of Neurology, Neuro-Muscular Center, National
Omuta Hospital); Masatoshi Naito and Jun Arimizu
(Department of Orthopaedic Surgery, Faculty of Medi-
cine, Fukuoka University); Takashi Nakagawa, Hiro-
fumi Harada, and Takayuki Sueta (Department of
Otorhinolaryngology, Faculty of Medicine, Fukuoka
University); Toshihiro Kikuta and George Umemoto
(Department of Oral and Maxillofacial Surgery, Faculty
of Medicine, Fukuoka University); Eiichi Uchio and
Hironori Migita (Department of Ophthalmology,
Faculty of Medicine, Fukuoka University); Kenichi
Kazuki, Yoichi Ito, and Hiroyoshi Iwaki (Department
of Orthopaedic Surgery, Osaka City University Gradu-
ate School of Medicine); Kunihiko Siraki and Shinsuke
Ataka (Department of Ophthalmology and Visual
Sciences, Osaka City University Graduate School of
Medicine); Hideo Yaname and Rie Tochino (Depart-
ment of Otolaryngology and Head and Neck Surgery,
O s a k aC i t yU n i v e r s i t yG r a d u a t eS c h o o lo fM e d i c i n e ) ;
Teruichi Harada (Plastic and Reconstructive Surgery,
O s a k aC i t yU n i v e r s i t yG r a d u a t eS c h o o lo fM e d i c i n e ) ;
Yasushi Iwashita, Motoyuki Shimizu, Kenji Seki, and
Keiji Ando (Department of Orthopedic Surgery, Utano
National Hospital).
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